Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB059872 in Sickle Cell Disease
NCT03132324Phase 1Terminated
- Sponsor
- Incyte
- Start
- Apr 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of incb059872 in sickle cell disease (SCD) (3 arms), sponsored by Incyte. Primary endpoints: Safety and tolerability of INCB059872 assessed by monitoring frequency, duration, and severity of adverse events and Change in fetal hemoglobin (HbF) from baseline. Started Apr 2017; status: terminated.
02
Drugs
incb059872
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03132324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132324.